Trial · NCT03252249
Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
NCT03252249, Phase 4, Completed, University of Edinburgh; results first posted 2026-01-28
3 sourcestrials-2026-11-12-0.4.0
Download JSON
Cite this record
ConductScience Library. Duration of Dual Anti-Platelet Therapy (DUAL-ACS). Trials, record NCT03252249. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03252249
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
- NCT number
- NCT03252249
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 5,094 participants, actual
- Lead sponsor
- University of Edinburgh
- Conditions
- Acute Coronary Syndrome, Coronary Artery Disease
- Interventions
- 3 months dual anti-platelet therapy, 12 months dual anti-platelet therapy
- First posted
- 2017-08-17
- Last updated
- 2026-11-03
- Results first posted
- 2026-01-28
- Limitations and caveats
The major limitation is that early trial termination meant the target sample size was not achieved, leaving an underpowered trial which was unable to address its primary endpoint. The recruitment suspension due to COVID-19, and the subsequent delays in re-opening of the study sites and lack of staff capacity significantly affected recruitment.
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time-to-event: All-cause Mortality | Date of index MI to 15 months | Restricted Mean Survival Time |
| Primary | Incidence: All-cause Mortality | Date of index MI to 15 months | Occurrence of event |
| Secondary | Time-to-event: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | Date of MI to 15 months | Restricted Mean Survival Time |
| Secondary | Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | Date of MI to 15 months | Occurrence of event |
| Secondary | Time-to-event: Non-cardiovascular Death (Including Fatal Bleeding) | Date of MI to 15 months | Restricted Mean Survival Time |
| Secondary | Incidence: Non-cardiovascular Death (Including Fatal Bleeding) | Date of MI to 15 months | Occurrence of event |
| Secondary | Time-to-event: Major Fatal and Non-fatal Bleeding | Date of MI to 15 months | Restricted Mean Survival Time |
| Secondary | Incidence: Major Fatal and Non-fatal Bleeding | Date of MI to 15 months | Occurrence of event |
| Secondary | Time-to-event: Gastrointestinal Bleeding | Date of MI to 15 months | Restricted Mean Survival Time |
| Secondary | Incidence: Gastrointestinal Bleeding | Date of MI to 15 months | Occurrence of event |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes27
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time-to-event: All-cause Mortality | Date of index MI to 15 months | Intention to Treat Population. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | days | MEAN |
| PRIMARY | Incidence: All-cause Mortality | Date of index MI to 15 months | Intention to Treat Population. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time-to-event: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | Date of MI to 15 months | The intention to treat (ITT) principle. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | days | MEAN |
| SECONDARY | Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | Date of MI to 15 months | The intention to treat (ITT) principle. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | participants | NUMBER |
| SECONDARY | Time-to-event: Non-cardiovascular Death (Including Fatal Bleeding) | Date of MI to 15 months | Intention to Treat Population. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | days | MEAN |
| SECONDARY | Incidence: Non-cardiovascular Death (Including Fatal Bleeding) | Date of MI to 15 months | The intention to treat (ITT) principle. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | participants | NUMBER |
| SECONDARY | Time-to-event: Major Fatal and Non-fatal Bleeding | Date of MI to 15 months | Intention to Treat Population. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | days | MEAN |
| SECONDARY | Incidence: Major Fatal and Non-fatal Bleeding | Date of MI to 15 months | The intention to treat (ITT) principle. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | participants | NUMBER |
| SECONDARY | Time-to-event: Gastrointestinal Bleeding | Date of MI to 15 months | Intention to Treat Population. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | days | MEAN |
| SECONDARY | Incidence: Gastrointestinal Bleeding | Date of MI to 15 months | The intention to treat (ITT) principle. Patients were analysed according to their allocated intervention, irrespective of whether the patient's actual management complied with the allocated intervention. | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 outcomesResults by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time-to-event: All-cause Mortality | 3 Months Dual Anti-platelet Therapy | 447.337 | Standard Error 1.0542 | days | |
| Time-to-event: All-cause Mortality | 12 Months Dual Anti-platelet Therapy | 445.196 | Standard Error 1.1741 | days | |
| Incidence: All-cause Mortality | 3 Months Dual Anti-platelet Therapy | 68 | Participants | ||
| Incidence: All-cause Mortality | 12 Months Dual Anti-platelet Therapy | 87 | Participants | ||
| Time-to-event: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | 3 Months Dual Anti-platelet Therapy | 442.881 | Standard Error 1.2908 | days | |
| Time-to-event: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | 12 Months Dual Anti-platelet Therapy | 440.736 | Standard Error 1.3565 | days | |
| Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | 3 Months Dual Anti-platelet Therapy | 104 | participants | ||
| Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | 12 Months Dual Anti-platelet Therapy | 127 | participants | ||
| Time-to-event: Non-cardiovascular Death (Including Fatal Bleeding) | 3 Months Dual Anti-platelet Therapy | 452.453 | Standard Error 0.5873 | days | |
| Time-to-event: Non-cardiovascular Death (Including Fatal Bleeding) | 12 Months Dual Anti-platelet Therapy | 452.593 | Standard Error 0.5285 | days |
1 to 10 of 54Source ClinicalTrials.gov
See all 54 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 3 Months Dual Anti-platelet Therapy | 2,526 | |
| Overall Study | STARTED | 12 Months Dual Anti-platelet Therapy | 2,526 | |
| Overall Study | COMPLETED | 3 Months Dual Anti-platelet Therapy | 2,526 | |
| Overall Study | COMPLETED | 12 Months Dual Anti-platelet Therapy | 2,526 | |
| Overall Study | NOT COMPLETED | 3 Months Dual Anti-platelet Therapy | 0 | |
| Overall Study | NOT COMPLETED | 12 Months Dual Anti-platelet Therapy | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 3 Months Dual Anti-platelet Therapy | 68 | 2,526 |
| Total, all-cause mortality | 12 Months Dual Anti-platelet Therapy | 87 | 2,526 |
| Total, other adverse events | 3 Months Dual Anti-platelet Therapy | 0 | 2,526 |
| Total, other adverse events | 12 Months Dual Anti-platelet Therapy | 0 | 2,526 |
| Total, serious adverse events | 3 Months Dual Anti-platelet Therapy | 0 | 2,526 |
| Total, serious adverse events | 12 Months Dual Anti-platelet Therapy | 0 | 2,526 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons16
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Non-cardiovascular Death (Including Fatal Bleeding) | Trial comparisons |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Major Fatal and Non-fatal Bleeding | Trial comparisons |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Gastrointestinal Bleeding | Trial comparisons |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Cardiovascular Mortality (Cardiac and Non-cardiac) | Trial comparisons |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: All-cause Mortality | Trial comparisons |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Blood Transfusion | Trial comparisons |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Thrombotic Stroke | Trial comparisons |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Stent Thrombosis | Trial comparisons |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | Trial comparisons |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Coronary Revascularisation | Trial comparisons |
1 to 10 of 16
See all 16 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03252249
GET https://conductscience.org/api/trials/v1/NCT03252249/registered?page=2